| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.5M | -5.0% | +7.5% |
| SG&A Expense | $2.2M | -18.4% | +4.7% |
| Operating Income | -$6.7M | +9.9% | -6.6% |
| Net Income | -$6.5M | +8.6% | -8.1% |
| EPS (Basic) | -$0.11 | +8.3% | +0.0% |
| EPS (Diluted) | -$0.11 | +8.3% | +0.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.6M | -61.3% | -86.6% |
| Current Assets | $4.2M | -52.1% | -80.5% |
| Total Assets | $25.0M | -13.4% | -41.6% |
| Current Liabilities | $6.8M | +1.7% | +8.9% |
| Total Liabilities | $23.7M | -1.1% | -3.4% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$17.6M | — | — |
| Capital Expenditures | $899K | — | — |
| Investing Cash Flow | -$899K | — | — |
| Financing Cash Flow | $2.7M | — | — |
| Free Cash Flow | -$18.5M | — | — |
| $1.3M |
| -73.3% |
| -92.9% |